Michelle Maskaly

Gil Van Bokkelen, CEO and co-founder of Athersys, talks about a pivotal moment during medical school that led him and his co-founders to eventually launch Athersys, the decision to start the company in Ohio instead of his native Northern California, and the secret to staying resilient in the c-suite, even when facing extraordinary challenges.

New Jersey is still a top pick for companies when it comes to pharma.

Korean biotech opens first U.S. headquarters in New Jersey to better control clinical trials as it looks for strategic partnerships in the U.S.

Enzychem Lifesciences explains why the Korean biotech decided to open U.S. headquarters, as well as gives an update on their most recent clinical trials.

Hear what Sanofi looks for when they decide to form a partnership with another company.

Former NFL star and current sports broadcaster, Solomon Wilcots talks about the intersection of sports and biopharma. He discusses traumatic brain injuries and whether or not the NFL is doing enough about it, projects he has been working on that match professional athletes who are passionate about a certain disease with biopharma companies, and how lessons from the football field can be applied to the boardroom.

Jonathan Kraft shares his family's secrets on what it takes to lead a successful organization, while also creating lasting brand power.

From AI to Alexa, experts in specialty pharma ponder the possibilities for high tech and the patient journey.

Michelle and Christen host one of Pharm Exec's Emerging Pharma Leaders, Sabina Ewing, vice president of business technology for Pfizer, and discuss the difference and importance of mentoring and sponsoring in business and pharma.

Episode 9 features the entire Pharm Exec editorial team, discussing each selection of this year's Brand of the Year and why we chose them.

Otsuka Pharmaceutical’s President and CEO of Development and Commercialization William Carson explains the initial growing pains the company went through with their technology company partner in the early development stages of the first U.S. FDA approved digital medicine system.

Known as the city that never sleeps, attracting and keeping the scientific breakthroughs in-state is something that’s keeping New York economic and academic developers up at night.

William Carson, president & CEO of Otsuka Pharmaceutical’s development and commercialization, talks about the challenges facing the pharmaceutical industry when it comes to the massive amounts of data being collected.

Episode 8 highlights Tim Sullivan, CFO of Apellis Pharmaceuticals, who provides listeners an inside look at what it takes to be the CFO of a development-stage biotch company, and what business skills someone needs to succeed in that type of position.

Take a sneak peek at what the future of home healthcare could look like with the use of robotics and artificial intelligence.

Consumers are paying more out of pockets for pharmaceutical drugs and healthcare services, as high deductible plans become more and more popular.

John Cervione, managing partner of Blue Fin Group, explains the top trend impacting executives in the specialty pharma industry.

The pharmaceutical industry needs to be paying more attention to consumer purchase habits.

Albert Thigpen, president and chief operating officer of CastiaRx, talks about how pharmaceuticals companies could be using devices such as Amazon’s Alexa to help improve patient adherence and the overall patient journey.His remarks come after a seminar at Asembia’s Specialty Pharmacy Summit in Las Vegas. 

A former biology major, biotech investment banker, and venture capitalist, Tim Sullivan brings that sought-after melding of business and scientific perspectives to his role as chief financial officer for Apellis, a clinical-stage drug company hopeful of ushering in novel protein inhibitors form autoimmune disease.

John Cervione, managing partner of Blue Fin Group, talks briefly about Amazon’s foray into the healthcare and pharma industries.

On episode 7, Pharm Exec editors discuss key takeaways from a variety of industry conferences that took place across the globe.

On episode 6, Michelle and Christen talk to Lara Sullivan, founder and president of SpringWorks Therapeutics, about the differences in working for legacy pharma vs. small biotech start-ups.

Senior leaders in the life sciences share stories on making the jump from the pharma to biotech worlds-and the innate drivers behind such moves.

From her early calling as a doctor to assuming critical leadership roles at the front lines of the world’s most pressing population health issues, Julie Gerberding, this year's Healthcare Businesswomen’s Association Woman of the Year, has remained steadfast in her life’s mission-help the many, help the one.

Michelle and Christen talk with William Soliman about Accreditation Council for Medical Affairs (ACMA).

Outcomes-based contracting could be a potential game changer in linking drug cost with value, boosting healthcare efficiency, and ensuring that appropriate patients benefit from innovative medicines. But several complex challenges remain in the bid to make this model a mainstay.

In this episode, Michelle and Christen talk to Editor-in-Chief Lisa Henderson and European Editor Julian Upton about outcomes-based contracting from the March issue.

How one pharma vet helped create the first industry-wide training standards for aspiring medical affairs professionals. 

In this episode, Christen and Michelle talk to Devyn Smith, chief strategy officer and head of operations for Sigilon Therapeutics, on the topic of pharma's reputation, both in the US and Europe.